抗逆转录病毒药物治疗HIV感染新进展

Antiretroviral drugs for HIV infection

通过抗逆转录病毒药物（ARVs）对HIV进行长期的有效抑制是现阶段治疗HIV感染最有效的手段。ARVs推广以来也出现了不少问题，如药物不良反应、服药负担等，影响了患者接受治疗的意愿和依从性，耐药问题导致部分患者未能取得良好的病毒学疗效。为了应对上述问题，当前研究聚焦在长效ARVs，固定剂量组合与单片疗法，二联口服疗法和新化学药物单体研发等方面，这些进展将大大提高ARVs的可接受性，有助于提高患者的依从性，改善患者的生活质量，此文就现阶段ARVs研究进展展开综述。

Long-term suppressive therapy with antiretroviral drugs （ARVs） is the key treatment for HIV infection. With the application of ARVs, there are a lot of problems, such as side effects and medication burden that can affect patients＇ compliance and drug resistance that can cause bad virological effects. In order to solve the above problems, the current ARVs research focuses on long-acting ARVs, fixed-dose combinations and the single dose regimens （SDRs）, two couplet oral therapy and new chemical drug R＆D, et al. These advances will greatly increase the acceptability of ART, and improve the compliance of patient and their quality of life.